Psybina RX

Psybina RX is a **psilocybin-based small molecule psychedelic formulation** developed by Numinus Bioscience, part of Numinus Wellness. It is designed to stably deliver naturally derived psilocybin together with other synergistic compounds in a complex matrix, using patent-pending technology intended to improve stability, bioavailability, and manufacturing efficiency relative to synthetic psilocybin. Its pharmacology is expected to be driven primarily by psilocybin and its active metabolite psilocin, which act as agonists at the serotonin 5-HT2A receptor, the principal receptor associated with psychedelic effects and the proposed therapeutic effects in psychiatric disorders. Psybina RX has been evaluated clinically in a Phase 1 trial in healthy volunteers in Vancouver using synthetic psilocybin as a comparator; specific therapeutic indications for the formulation itself were not clearly established in the provided source material, although psilocybin broadly is being investigated in disorders such as depression, anxiety, and substance use disorders.

Brand names

PSYBINA RX

Other names

natural psilocybin formulation